Oxybutynin Chloride Tablet, Extended Release
Product Images NDC 43353-285

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 43353-285). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 5 mg (43353 285 30)

Label for Oxybutynin Chloride Extended Release 5 mg oral tablets, containing 30 tablets per bottle. The label shows the product name, strength, and quantity, along with storage instructions and repackager information from Aphena Pharma Solutions - Tennessee, LLC. It includes multiple barcodes and the statement RX Only.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Chemical Structure (Oxybutynin 1)

Chemical structure diagram of Oxybutynin Chloride, showing its molecular arrangement with indicated chemical bonds and groups, including a phenyl group, an ester linkage, and a quaternary ammonium salt associated with hydrochloride (HCl).*

FDA Label Image

Figure 1 (Oxybutynin 2)

A line graph comparing mean plasma R-oxybutynin concentration over 24 hours between oxybutynin chloride extended-release tablets and oxybutynin 5 mg taken three times daily (TID). The x-axis represents time in hours, and the y-axis represents mean plasma concentration in ng/mL, showing fluctuating concentration levels for both formulations with error bars indicating variability.*

FDA Label Image

Figure 2 (Oxybutynin 3)

A line graph showing mean R-Oxybutynin plasma concentration (ng/mL) over time (hours). The graph displays data points from 0 to 24 hours, with concentrations ranging approximately from 0.5 to 0.7 ng/mL, illustrating the plasma level profile after dosing.*

FDA Label Image

Figure 2 (Oxybutynin 4)

A bar chart comparing the mean change (± standard deviation) in episodes per week from baseline for Oxybutynin Chloride extended-release tablets versus placebo. The horizontal axis shows numeric values ranging from -40 to 40, representing the mean change in episodes per week.*

FDA Label Image

Figure 3 (Oxybutynin 5)

A horizontal bar chart illustrating the mean change in episodes per week from baseline for oxybutynin chloride extended-release tablets. The chart shows the mean change with standard deviation bars around the mean value for oxybutynin, with values positioned along a horizontal axis ranging approximately from -40 to 40 episodes per week.*

FDA Label Image

Figure 4 (Oxybutynin 6)

A bar chart displaying mean change in episodes per week from baseline, comparing oxybutynin chloride extended-release tablets to placebo. The x-axis shows mean change with standard deviation, ranging from -40 to 40 episodes per week. The comparison highlights efficacy data for oxybutynin chloride extended-release tablets vs placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.